Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Morgan Stanley (MS) vs Pfizer Inc (PFE) Price & Performance

Morgan StanleyTrade
Pfizer IncTrade

Price performance (Past 24H)

Key statistics

Morgan Stanley vs Pfizer Inc — how do they compare? Morgan Stanley trades at $215.3 (market cap $338.50B), while Pfizer Inc trades at $26.6 (market cap $154.18B). The key difference: Morgan Stanley is far larger — about 2.2× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.36%). Which is the better fit depends on your goals.

MSPFE
Market Cap
$338.50B$154.18B
Sector
FinancialsHealth
52-Week High
$228.42$28.56
52-Week Low
$143.88$23.60
Dividend Yield
2.14%6.36%
Volume
29,869,932
Enterprise Value
$205.67B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Morgan Stanley

Morgan Stanley (MS) trades at $215.1, down 0.54% on the day, with a neutral technical signal and key support at $214. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $3.46 surpassing expectations of $2.89. Revenue growth accelerated to $66.0B in 2025, and net income margin improved to 25.56%. Recent news highlights Morgan Stanley's role in leading Anthropic's IPO and expanding AI integration in wealth management.

The outlook remains positive with a consensus price target of $239.58, implying 11% upside. Strengths include robust profitability and strategic initiatives, but risks involve volatile cash flows from operations and high leverage. Analyst sentiment is bullish with 56% buy ratings, though investors should monitor debt levels and market volatility.

Pfizer Inc

Pfizer (PFE) trades at $26.62, down 0.45% today, with a bullish technical signal from moving averages and a consensus analyst price target of $27.86. The company reported three consecutive quarterly earnings beats in 2026, with Q3 2026 EPS expected at $0.79. Revenue for 2025 was $62.58 billion, with a net income margin of 12.41%, though 2026 projections show a decline to 6.8%. Positive news highlights pipeline advancements in obesity and oncology therapies.

Pfizer presents a mixed outlook: bullish technicals and analyst support contrast with declining profit margins and patent cliff risks. Investment opportunities include a solid dividend yield and catalyst-rich pipeline in 2026, but risks involve revenue volatility post-COVID and competitive pressures. The stock's current valuation at a P/E of 35.59 may limit near-term upside absent earnings acceleration.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Morgan Stanley

Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.

Read more on MS

About Pfizer Inc

Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.

Read more on PFE